Protease Regulation in COPD: An Immunohistochemical Analysis of COPD Tissue

Protease Regulation in COPD: An Immunohistochemical Analysis of COPD Tissue



Case Study





Due date:



The risk of developing Chronic Obstructive Pulmonary Disease (COPD) is higher in heavy smokers. COPD is characterized by poorly reversible lung function failure. The process of inflammatory cell recruitment is contributed by smoke-induced inflammation involving neutrophils and macrophages, which have the ability to release proteolytic enzymes. These enzymes are known to fight lungs pathogens. The production and secretion of these enzymes is carefully regulated by inhibitors such as down-regulation when not needed. In COPD cases, this enzyme appears to be dysregulated. This research utilized immunohistochemical (IHC) techniques to characterize the level of expression of protease and inhibitor in paraffin that has been embedded with lung tissue resections obtaine from patients with respiratory disease. The analysis of the findings involved the determination of correlation of protease and inhibitor expression and in relation to morphological appearance of lung resections and patient demographics that included lung function and smoking pack year history.


Chronic Obstructive Pulmonary Disease (COPD) is also referred to as Chronic Obstructive Lung Disease (COLD) or Chronic Obstructive Airway Disease (COAD) (Reilly et al. 2011). COPD is a type of obstructive lung disease that is characterized by progressive and chronically poor airflow that makes it hard to breathe (Vestbo 2013). If accompanied with coughing, the patient produces large quantities of mucus. The disease is also characterized by wheezing, shortness of breath, and chest tightness among other symptoms (Ward 2012). Cigarette smoking has been identified as the leading cause of COPD. Other etiological factors or major contributors of COPD include air pollution, chemical fumes, and dust among others (Vestbo 2013). In order to understand COPD, it would be better to understand the functional principles of the lung. The lung is an organ that is specialized for respiration through breathing. The air that is breathe moves into the lung through the windpipe (bronchial) that divides into thousands of smaller tubes and tubules referred to as bronchioles within the lungs. The terminals of these tubules are the air sacs referred to as alveoli, which are bunches of tiny rounded air sacs. The alveoli are surrounded by capillaries (small blood vessels), which run through the surface of the alveoli. When the air that is breathed reaches the alveoli, the oxygen crosses through the walls of the alveoli and the capillaries into the blood in the lumen of the capillaries. Simultaneously, the carbon dioxide (waste gas) carried in the blood moves in the opposite direction i.e. from the capillaries into the alveoli from which it is excreted through breathing out (Decramer et al 2012). An individual with COPD has a characteristic less air flow in and out of the airways because of one or more of the following features. First, the alveoli and airways lose their elasticity. Second, the individual exhibit destroyed walls between multiple alveoli (Vestbo 2013). The destruction of the alveoli wall can result to formation of fewer large alveoli (Weitzenblum & Chaouat 2009). Third, the patient has inflamed or thickened wall of the airways. Fourth, the airways produce more mucus than usual, which can result to clogging.

There are two main conditions that are associated with COPD and they include emphysema and chronic bronchitis (Vestbo 2013). The emphysema condition is characterized by damaging of the walls between many of the air sacs, which results to the loss of shape of alveoli that become floppy (Vestbo 2013). It also results to destruction of the alveoli walls leading to fewer and large air sacs instead of normal many and tiny alveoli (Rabe et al. 2007). This in turn results to reduced amount or rate of gas exchange in the lungs. On the other hand, the chronic bronchitis condition is characterized irritated and inflamed lining of the airways resulting to thickening of the lining (Laniado-Laborín 2009). The condition is also associated with production of thick mucus in the airways that makes it hard to breathe (Reilly et al. 2011). Many people with COPD have both conditions – emphysema and chronic bronchitis. In this regard, the occurrence of either condition or both is referred by the general term COPD (Spiro 2012).

COPD has been identified as a major cause of disability and one of the leading contributors of mortality (Mathers & Loncar 2006). The disease has been associated with high incidence and prevalence rates in many countries across the globe. It has also been established through research that many people may be having the disease but do not know about its development and progression (Reilly et al. 2011). The development of COPD is usually spontaneous and thus symptoms usually worsen with time, which results to reduced ability to perform routine activities (Vestbo 2013). The progression of the disease to severe stages can prevent the patient from performing even the basic activities such as cooking, walking, and taking care of other personal needs. According to hospital records, most of the positive COPD diagnosis usually occur in middle-age, older adults, and the aged (Decramer et al 2012). The disease is non-communicable and thus cannot be transmitted from person to person. To date, there is no cure of COPD yet and there is also no medical/ therapeutic mechanism for reversing the damage caused to the airways and lungs (Vestbo 2013). The only existing best management mechanisms involves lifestyle changes, which makes the patient feel better, increase activity, and slows the progression of the disease (National Institute for Health and Clinical Excellence 2010; Morrison & Goldstein 2013).

Smoking is the leading cause of COPD because the inhalation of cigarette smoke causes irritation and inflammation of the lungs resulting to scarring (Nathell et al. 2007). Consistent smoking leads to permanent changes in the lungs resulting to thickening of the airways and increased production of mucus. These processes are associated with damaging of the delicate walls of the alveoli leading to emplysema and the lungs lose its elasticity. Additionally, the condition also causes the smaller airways to scar and thus inflame to become narrower. These changes results to the commonest symptoms of COPD that include breathlessness, coughing, and phlegm (Vestbo 2013). Apart from cigarette smoking, inhalation of fumes and particles/ dust, air pollution, and genetic disorders have also been associated with development and progression of COPD but the incidences are rare. These rare etiologies have been associated with inhalation of secondhand smoke and other related agents from the environment particularly from the work place (occupational) hazards (Brulotte & Lang 2012). In the case of genetic etiologies, a condition referred to as alpha-1 antitrypsin deficiency has been associated with COPD (Reilly et al. 2011). People with this condition have been identified to having low level of alpha-1 antitrypsin (AAT), which is a protein that is synthesized in the liver (Mahler 2006). Individuals with low level of AAT proteins are at risk of developing lung damage that can result to irritation and inflammation, which are the initial inducing events of developing COPD. The progression of COPD can occur very quickly if the etiological factors interact with the lung high at a increased rate. For instance, smoking and inhalation of other environmental –based lung irritants such as fumes can worsen the progression of COPD (Gruber 2008; Holland et al. 2012). It should be noted that COPD is quite uncommon in individuals with asthma though some people with this condition can develop COPD. Asthma is known to be a chronic lung condition that causes inflammation and narrowing of the airways and successful treatment usually reverse this inflammation and narrowing (Reilly et al. 2011). In case an individual with asthma does not seek appropriate medication then COPD can develop.

Based on the information on etiology of COPD, the leading risk factor for COPD is smoking. Multiple studies have identified that most of the people that smoke have COPD smoke (Decramer et al 2012). Secondhand smoke (exhaled smoke from other smokers) has been found be the leading cause and risk factor of COPD in the non-smoking population (Reilly et al. 2011). It has also been established that smokers from families with history of COPD are at a higher risk of developing COPD. Exposure and inhalation of other lung irritants have been identified as potential risk factors for COPD if the exposures are long-term (Mandell et al. 2009). Most people with COPD are at least 40 years and most of them start to develop symptoms (Mathers & Loncar 2006). It is uncommon for people less than 40 years of age to develop the disease. However, the development of the disease in young population has been associated with other conditions such as alpha-1 antitrypsin deficiency, which is a genetic condition and failure of treatment of other respiratory diseases and conditions such as Asthma and pneumonia (Mathers & Loncar 2006; Lomborg, 2013). It is important to note that the initial stage of COPD is not associated with any symptoms and if any only the wild symptoms are exhibited.


Pre-treatment of the Buffer Recipies

  1. Citrate Buffer

The preparation of the citrate buffer involved dissolving 2.1 g of Tri-sodium citrate in 1000ml of Dh2O. Its pH was adjusted to 6.0 using few drops of 1M HCl.

  1. 1 mM EDTA Buffer

The EDTA Buffer was prepared by dissolving 0.37g of EDTA in 1000 ml of water and the PH adjusted to 8.0.

  1. Tris-EDTA Buffer

Tris-EDTA buffer was prepared by dissolving 1.21g of Tris Base (C4H11NO3, C10N14N2Na2O8.2H2O). It was added with 0.37g of EDTA (Ethylene diamine – NNNN – tetra acetic acid di-sodium salt). The pH was adjusted to 9.0 and added with 0.5 ml Tween-20 and mixed well.

Preparation of TBS 10X (Concentrated Tris-Buffered Saline) – 1 Liter

The TBS 10x was prepared using 24 g of Tris base (Formula weight: 121.1 g) and 88 g of NaCl (Formula weight: 58.4 g) that were dissolved in 900 ml of distilled water. The pH was adjusted to 7.6 using 12N of HCl. It was then added with distilled water to obtain the final volume of 1 liter. From this solution, 1X solution was prepared by mixing 1 part of the 10X solution with 9 parts of distilled water and the pH was adjusted to 7.6 again. In this regard, the final molar concentrations of the 1X solution were 20 mM Tris and 150 mM NaCl.

Preparation of 1X TBS/ Tween

This solution was prepared by dissolving 500 μL of Tween-20 to 500 ml of 1X TBS.

Preparation of Biotinylated Secondary Antibody

This involved adding 15 μL of normal blocking serum stock to 1 ml PBS in the mixing bottle and then adding one 5 μL of biotinylated antibody stock.

Preparation of Hydrogen Peroxide (H2O2)

This involved mixing 48.5 ml of methol and 1.5 ml of hydrogen peroxide (3%).

Preparation of ABC Reagent

This involved the addition of exactly 2 drops of REAGENT A to 5 ml of TBS in the ABC Reagent large mixing bottle. Thereafter, exactly 2 drops of REAGENT B was added to the same mixing bottle and mixed immediately. The VECTASTAIN ABC Reagent was allowed to stand for about 30 minutes before use. Both bottles were shaken well then added with 1 drop (approx. 30 μl) of ImmPACT DAB Chromogen concentrate to 1 ml of ImmPACT diluents and mixed well. Note that ABC consisted of TBS + A + B.

The slides were blocked using normal serum. The normal saline was obtained from the same animal in which the secondary antibody was obtained. This ensured that any non-specific or background staining from secondary antibody was blocked. The normal serum would bind to non-specific targets on the tissue or cells. The usual dilution of normal serum was set at 15 μl per 1 ml. The primary antibodies used in this research were mouse anti human and they included AE1/ AE3, CCR5, CCR7, IL-6, and IL-8. The secondary antibody was the horse anti mouse and blocking was done in horse serum (i.e. this involved the use of the mouse kit). The SA100 was the rabbit anti human and its secondary was goat anti rabbit and blocking was done in the goat serum (This involved the use of rabbit kit). The slides were blocked using the normal serum that was obtained from the same animal from which the secondary antibody was obtained.

Immunohistochemistry (IHC) of the FFPE Tissue

This process involved standard single label immunoperoxidase and was accomplished within 2 days. The activities of the first day included the following. The sections were de-waxed through xylene (2 x 5 minutes). Thereafter, the sections were dehydrated through ethanol: 100% for 5 minutes; 90% ethanol for 3 minutes; 75% ethanol for 2 minutes; and 50% ethanol for 1 minute. They were then placed under running water for 5 minutes and carefully dry slide with tissue paper (It was important not to wipe off the sample). The samples were pre-treated in appropriate buffer at pH 6. Pre-treatment involved placing the slides in a glass coplin jar. The coplin jar was placed into 1L beaker and filled with buffer. The beaker was covered with cover glass and placed into the microwave that was operated at 1200w (in 116) – 20 minutes, 60% power. It was important not to place only the coplin jar in the microwave since it would explode and thus generating a risk of cuts and burns. With the use of heatproof gloves, the beaker/coplin jar assembly and the sections were allowed to cool in the buffer for 20 minutes. The slides were placed in running water for 5 minutes and then carefully dry slide with tissue paper without touching the sample. The sections were drawn around using the PAP pen. This process involved the use of 100 ml of diluted antibody and blocked in vector normal serum (30 minutes at RT). The primary antibody was incubated in dilute normal serum for 2 hours at room temperature.

The activities of the second day involved the following. The samples were washed in TBStween (3 x 3 minutes). It was incubated in vector biotinylated secondary antibody (30 minutes at room temperature). Thereafter, it was washed in TBStween (3 x 3 minutes) and the endogenous peroxidase was blocked by incubating in 3% H2O2 in methanol for 30 minutes at room temperature. ABC was prepared in Elite Px 30 minutes before use. The sample was washed in running water for 5 minutes and in TBS for another 5 minutes and incubated in ABC-Px solution for 30 minutes at room temperature. Thereafter, the samples were washed in TBStween (3 x 3 minutes) and incubated in DAB substrate before visualization under microscope and dH2O was used to stop the reaction.




Reference List

Brulotte, CA and Lang ES 2012, Acute exacerbations of chronic obstructive pulmonary disease in the emergency department, Emerg. Med. Clin. North Am., vol. 30, no. 2, pp. 223–247

Decramer M, Janssens W and Miravitlles M 2012, Chronic obstructive pulmonary disease, Lancet, vol. 379, no. 9823, pp. 1341–1351

Gruber, P 2008, The Acute Presentation of Chronic Obstructive Pulmonary Disease In the Emergency Department: A Challenging Oxymoron, Emergency Medicine Practice, vol. 10, 11

Holland, AE, Hill, CJ, Jones, AY and McDonald, CF 2012, In Holland, AE, Breathing exercises for chronic obstructive pulmonary disease, Cochrane Database Syst Rev, vol. 10, CD008250, View on 27 January 2015, doi:10.1002/14651858.CD008250.pub2

Laniado-Laborín, R 2009 Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21st century, International journal of environmental research and public health, vol. 6, no. 1, pp. 209–224

Lomborg, B 2013, Global problems, local solutions : costs and benefits, Cambridge University Press, Cambridge, pp. 143

Mahler, DA 2006, Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease, Proceedings of the American Thoracic Society, vol. 3, no. 234–238

Mandell, JK, Stoller, FA, Michota Jr., BF 2009, The Cleveland Clinic Foundation intensive review of internal medicine (5th ed.), Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA

Mathers, CD and Loncar, D 2006, Projections of Global Mortality and Burden of Disease from 2002 to 2030, PLoS Med., vol. 3, no. 11, e442. View on 27 January 2015, doi:10.1371/journal.pmed.0030442

Morrison, NE and Goldstein, RS 2013, Evidence-based practice of palliative medicine, Elsevier/Saunders, Philadelphia, p. 124

Nathell, L, Nathell, M, Malmberg, P, and Larsson, K 2007, COPD diagnosis related to different guidelines and spirometry techniques, Respir. Res., vol. 8, no. 1, no. 89

National Institute for Health and Clinical Excellence 2010, Clinical guideline 101: Chronic Obstructive Pulmonary Disease, National Institute for Health and Clinical Excellence, London

Rabe, KF, Hurd, S, Anzueto, A, Barnes, PJ, Buist, SA, Calverley, P, Fukuchi, Y, Jenkins, C, Rodriguez-Roisin, R, Van Weel, C, and Zielinski, J 2007, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am. J. Respir. Crit. Care Med., vol. 176, no. 6, no. 532–55

Reilly, JJ, Silverman, EK, Shapiro, SD 2011, Chronic Obstructive Pulmonary Disease, In Longo, D, Fauci, A, Kasper, D, Hauser, S, Jameson, J and Loscalzo, J, Harrison’s Principles of Internal Medicine (18th ed.), McGraw Hill, pp. 2151–2159

Spiro, S 2012, Clinical respiratory medicine expert consult (4th ed.), Saunders, Philadelphia, PA

Vestbo, J 2013, Definition and Overview, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease, pp. 1–7

Vestbo, J 2013, Diagnosis and Assessment, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease

Ward, H 2012, Oxford Handbook of Epidemiology for Clinicians, Oxford University Press, Oxford, pp. 289–290

Weitzenblum, E and Chaouat, A 2009, Cor pulmonale, Chron Respir Dis, vol. 6, no. 3, pp. 177–85

World Health Organization 2008, WHO Report on the Global Tobacco Epidemic 2008: The MPOWER Package, World Health Organization, Geneva, pp. 268–309


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s